Interventional procedure overview of bioresorbable stent implantation to treat coronary artery disease
Closed for comments This consultation ended on at Request commenting lead permission
Abbreviations
Word or phrase | Abbreviation |
|---|---|
Acute coronary syndrome | ACS |
American College of Cardiology | ACC |
American Heart Association | AHA |
Academic Research Consortium | ARC |
Bioresorbable stents | BRS |
Bioresorbable vascular scaffold | BVS |
Coronary artery disease | CAD |
Coronary artery aneurysm | CAA |
Coronary heart disease | CHD |
Confidence interval | CI |
Drug-eluting stents | DES |
Device-oriented composite endpoint | DOCE |
Everolimus-eluting stent | EES |
Hazard ratio | HR |
Health technology assessment | HTA |
Intravascular ultrasound | IVUS |
Left circumflex artery | LCX |
Left anterior descending artery | LAD |
Major adverse cardiovascular event | MACE |
Magnesium-based bioresorbable scaffold | MgBRS |
Myocardial infarction | MI |
Optical coherence tomography | OCT |
Odds ratio | OR |
Percutaneous coronary intervention | PCI |
Patient-oriented composite endpoint | POCE |
Randomised controlled trials | RCTs |
Risk ratio | RR |
Reference vessel diameter | RVD |
Scaffold thrombosis | ScT |
Sirolimus eluting stent | SES |
ST elevation myocardial infarction | STEMI |
Target vessel revascularisation | TVR |
Target vessel failure | TVF |
Target lesion failure | TLF |
Target lesion revascularisation | TLR |
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions